Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 429268, 10 pages
Research Article

Randomized Clinical Trial on the Use of PHYSTA Freeze-Dried Water Extract of Eurycoma longifolia for the Improvement of Quality of Life and Sexual Well-Being in Men

1School of Medical Sciences, Universiti Sains Malaysia, Kelantan, 16150 Kubang Kerian, Malaysia
2Department of Science and Clinical Trial, Biotropics Malaysia Berhad, Level 52, Menara TM, Jalan Pantai Baharu, 50672 Kuala Lumpur, Malaysia
3Department of Life Sciences, Technical University of Braunschweig, 38106 Braunschweig, Germany

Received 15 May 2012; Accepted 26 September 2012

Academic Editor: Ching Lan

Copyright © 2012 Shaiful Bahari Ismail et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Eurycoma longifolia is reputed as an aphrodisiac and remedy for decreased male libido. A randomized, double-blind, placebo controlled, parallel group study was carried out to investigate the clinical evidence of E. longifolia in men. The 12-week study in 109 men between 30 and 55 years of age consisted of either treatment of 300 mg of water extract of E. longifolia (Physta) or placebo. Primary endpoints were the Quality of Life investigated by SF-36 questionnaire and Sexual Well-Being investigated by International Index of Erectile Function (IIEF) and Sexual Health Questionnaires (SHQ); Seminal Fluid Analysis (SFA), fat mass and safety profiles. Repeated measures ANOVA analysis was used to compare changes in the endpoints. The E. longifolia (EL) group significantly improved in the domain Physical Functioning of SF-36, from baseline to week 12 compared to placebo ( ) and in between group at week 12 ( ). The EL group showed higher scores in the overall Erectile Function domain in IIEF ( ), sexual libido (14% by week 12), SFA- with sperm motility at 44.4%, and semen volume at 18.2% at the end of treatment. Subjects with BMI 25 kg/m2 significantly improved in fat mass lost ( ). All safety parameters were comparable to placebo.